Skip to content

Study · Systematic review · 2022

8 results

Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.

Zaazouee MS, Hamdallah A, Helmy SK, Hasabo EA, Sayed AK, Gbreel MI, Elmegeed AA, Aladwan H, Elshanbary AA, Abdel-Aziz W, Elshahawy IM, Rabie S and 4 more

Show all authors

Elkady S, Ali AS, Ragab KM, Nourelden AZ

Diabetes & metabolic syndrome20 May 2022Cited by 30 (Europe PMC)

PMID35623229 (opens in a new tab)DOI10.1016/j.dsx.2022.102511 (opens in a new tab)PepBankPUB-35623229
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide 1 mg once weekly reduced HbA1c more than placebo at 30 weeks in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide 1 mg weekly lowered HbA1c more than placebo in a pooled analysis of trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction at 30 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    HbA1c mean difference
    −1.72%
    SC semaglutide 1 mg once weekly vs placebo, 30 weeks

    Source sentences

    Summary
    SC semaglutide 1 mg once-weekly showed higher reduction in HbA1c (MD = -1.72, 95% CI [-2.32; -1.12]), and fasting blood glucose (MD = -1.93, 95% CI [-2.81; -1.04]) versus placebo at 30 weeks and other timepoints.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide 1 mg once weekly reduced fasting blood glucose more than placebo at 30 weeks in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide 1 mg weekly lowered fasting blood sugar more than placebo in a pooled analysis of trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting blood glucose reduction at 30 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg once weekly · subcutaneous · 30 weeksAs given in this study (human).

    Measurements

    Fasting blood glucose mean difference
    −1.93
    SC semaglutide 1 mg once weekly vs placebo, 30 weeks

    Source sentences

    Summary
    SC semaglutide 1 mg once-weekly showed higher reduction in HbA1c (MD = -1.72, 95% CI [-2.32; -1.12]), and fasting blood glucose (MD = -1.93, 95% CI [-2.81; -1.04]) versus placebo at 30 weeks and other timepoints.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
  3. 03HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adults with type 2 diabetes, tirzepatide showed the highest efficacy, comparable to semaglutide.

    In plain wordsIn a pooled analysis in adults with type 2 diabetes, tirzepatide ranked highest for efficacy, similar to semaglutide.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedEfficacy ranking among agents
    Study

    n: not reported in source

    Comparator
    Other agents in the network
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide showed the highest efficacy, however, it was comparable to semaglutide.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
  4. 04HumanSystematic reviewEfficacy outcome

    In a network meta-analysis in adults with type 2 diabetes, semaglutide efficacy was comparable to that of tirzepatide.

    In plain wordsIn a pooled analysis in adults with type 2 diabetes, semaglutide worked about as well as tirzepatide.

    Peptide
    Semaglutide
    Outcome
    No significant changeEfficacy compared with tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide showed the highest efficacy, however, it was comparable to semaglutide.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
  5. 05HumanSystematic reviewSafety outcome

    In a network meta-analysis in adults with type 2 diabetes, adverse events with oral and subcutaneous semaglutide were comparable to placebo at most timepoints.

    In plain wordsIn a pooled analysis in adults with type 2 diabetes, side effects with semaglutide were similar to placebo at most timepoints.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse events versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Adverse events (ADs) were comparable to placebo with oral and SC semaglutide, oral sitagliptin, SC liraglutide, and oral empagliflozin at most timepoints.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
  6. 06HumanSystematic reviewSafety outcome

    In a network meta-analysis in adults with type 2 diabetes, adverse events with subcutaneous liraglutide were comparable to placebo at most timepoints.

    In plain wordsIn a pooled analysis in adults with type 2 diabetes, side effects with liraglutide were similar to placebo at most timepoints.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdverse events versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Adverse events (ADs) were comparable to placebo with oral and SC semaglutide, oral sitagliptin, SC liraglutide, and oral empagliflozin at most timepoints.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
  7. 07HumanSystematic reviewSafety outcome

    In a network meta-analysis in adults with type 2 diabetes, subcutaneous semaglutide 0.8 mg had among the highest gastrointestinal adverse event rates.

    In plain wordsIn a pooled analysis in adults with type 2 diabetes, semaglutide 0.8 mg had among the highest rates of stomach and gut side effects.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Other agents and doses in the network
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.8 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    However, SC semaglutide 0.8 mg and tirzepatide 10 mg groups had the highest gastrointestinal adverse events.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.
  8. 08HumanSystematic reviewSafety outcome

    In a network meta-analysis in adults with type 2 diabetes, tirzepatide 10 mg had among the highest gastrointestinal adverse event rates.

    In plain wordsIn a pooled analysis in adults with type 2 diabetes, tirzepatide 10 mg had among the highest rates of stomach and gut side effects.

    Peptide
    Tirzepatide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Other agents and doses in the network
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 mgAs given in this study (human).

    Source sentences

    Summary
    However, SC semaglutide 0.8 mg and tirzepatide 10 mg groups had the highest gastrointestinal adverse events.
    1 context sentence
    Summary · context
    Twenty-six included RCTs studied different doses of subcutaneous (SC) and oral semaglutide, tirzepatide, liraglutide, sitagliptin, canagliflozin, and empagliflozin compared with placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.